Acquisition of Erythropoiesis-Stimulating Medications

This tender concerns the acquisition of medications that stimulate erythropoiesis. Erythropoiesis is the process by which red blood cells are produced. These medications, often referred to as ESAs (Erythropoiesis-Stimulating Agents), are typically used to treat anemia, particularly in patients with chronic kidney disease, cancer patients undergoing chemotherapy, or individuals with certain other medical conditions. The procurement aims to secure a supply of these vital pharmaceutical products. The scope of the tender likely involves the purchase of specific ESAs, potentially including different formulations or dosages, to meet the therapeutic needs of patients under the care of the contracting entity. Bidders are expected to be licensed pharmaceutical suppliers capable of providing high-quality, safe, and effective erythropoiesis-stimulating medications that comply with all relevant pharmaceutical regulations and standards. The objective is to ensure consistent availability of these critical treatments for patients requiring them.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 126,354.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.